title: Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics.
abstract: Ongoing monitoring of neuroleptic-induced extrapyramidal side effects (EPS) is important to maximize treatment outcome, improve medication adherence and reduce re-hospitalization. Traditional approaches for assessing EPS such as Parkinsonism, tardive akathisia, or dyskinesia rely upon clinical ratings. However, these observer-based EPS severity ratings can be unreliable and are subject to examiner bias. In contrast, quantitative instrumental methods are less subject to bias. Most instrumental methods have only limited clinical utility because of their complexity and costs. This paper describes an easy-to-use instrumental approach based on handwriting movements for quantifying EPS. Here, we present findings from psychiatric patients treated with atypical (second generation) antipsychotics. The handwriting task consisted of a sentence written several times within a 2 cm vertical boundary at a comfortable speed using an inkless pen and digitizing tablet. Kinematic variables including movement duration, peak vertical velocity and the number of acceleration peaks, and average normalized jerk (a measure of smoothness) for each up or down stroke and their submovements were analyzed. Results from 59 psychosis patients and 46 healthy comparison subjects revealed significant slowing and dysfluency in patients compared to controls. We observed differences across medications and daily dose. These findings support the ecological validity of handwriting movement analysis as an objective behavioral biomarker for quantifying the effects of antipsychotic medication and dose on the motor system.
authors.affiliation: Department of Psychiatry, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA. mcaligiuri@ucsd.edu
authors.forename: Michael P
authors.initials: MP
authors.lastname: Caligiuri
authors.forename: Hans-Leo
authors.initials: HL
authors.lastname: Teulings
authors.forename: Charles E
authors.initials: CE
authors.lastname: Dean
authors.forename: Alexander B
authors.initials: AB
authors.lastname: Niculescu
authors.forename: James B
authors.initials: JB
authors.lastname: Lohr
mesh_terms: D000328:Adult; D000367:Age Factors; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000503:physiopathology; D001696:Biomechanical Phenomena / Q000187:drug effects; D003430:Cross-Sectional Studies; D005260:Female; D006236:Handwriting; D006801:Humans; D008297:Male; D008875:Middle Aged; D009068:Movement / Q000187:drug effects / Q000502:physiology*; D011569:Psychiatric Status Rating Scales; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology; D015203:Reproducibility of Results; D012559:Schizophrenia / Q000188:drug therapy; D012565:Schizophrenic Psychology; D012720:Severity of Illness Index; D012737:Sex Factors
chemical_list: D014150:Antipsychotic Agents
references.citation: Psychopharmacology (Berl). 2006 Dec;189(2):259-66
references.pmid: 17058105
references.citation: Ann Clin Psychiatry. 2002 Jun;14(2):123-9
references.pmid: 12238737
references.citation: Schizophr Res. 2003 Jun 1;61(2-3):123-36
references.pmid: 12729864
references.citation: J Psychiatr Pract. 2007 Jan;13(1):13-24
references.pmid: 17242588
references.citation: Pharmacopsychiatry. 1991 Jul;24(4):132-7
references.pmid: 1754609
references.citation: Br J Psychiatry. 1989 May;154:672-6
references.pmid: 2574607
references.citation: Drugs Aging. 2000 Nov;17(5):363-84
references.pmid: 11190417
references.citation: J Clin Psychopharmacol. 2002 Apr;22(2):196-200
references.pmid: 11910266
references.citation: Psychophysiology. 1998 Jul;35(4):431-7
references.pmid: 9643057
references.citation: Br J Psychiatry. 2008 Oct;193(4):279-88
references.pmid: 18827289
references.citation: Clin Pharmacol Ther. 2007 Apr;81(4):586-94
references.pmid: 17235331
references.citation: Am J Psychiatry. 2007 Sep;164(9):1310-2
references.pmid: 17728411
references.citation: Biol Psychiatry. 1997 Apr 1;41(7):830-3
references.pmid: 9084903
references.citation: Hum Mov Sci. 2006 Oct;25(4-5):510-22
references.pmid: 16647772
references.citation: Nervenarzt. 2000 May;71(5):373-9
references.pmid: 10846712
references.citation: Neuropsychopharmacology. 1992 Jun;6(4):231-9
references.pmid: 1632892
references.citation: Acta Psychiatr Scand Suppl. 1970;212:11-9
references.pmid: 4917967
references.citation: CNS Drugs. 2002;16(1):23-45
references.pmid: 11772117
references.citation: Psychol Rev. 1988 Jul;95(3):340-70
references.pmid: 3406245
references.citation: Psychol Aging. 1996 Jun;11(2):195-8
references.pmid: 8795047
references.citation: Schizophr Bull. 1987;13(2):261-76
references.pmid: 3616518
references.citation: Hum Mov Sci. 2009 Oct;28(5):633-42
references.pmid: 19692133
references.citation: Biol Psychiatry. 2001 Dec 1;50(11):873-83
references.pmid: 11743942
references.citation: Acta Psychiatr Belg. 1978 Jan-Feb;78(1):19-36
references.pmid: 645405
references.citation: Exp Neurol. 1997 Jul;146(1):159-70
references.pmid: 9225749
references.citation: J Clin Psychiatry. 2003;64 Suppl 12:5-19
references.pmid: 14640142
references.citation: CNS Drug Rev. 2004 Winter;10(4):317-36
references.pmid: 15592581
references.citation: Psychiatry Res. 1999 Feb 22;90(1):31-9
references.pmid: 10320209
references.citation: Int J Clin Pharmacol Ther. 2005 Aug;43(8):370-8
references.pmid: 16119512
references.citation: Int Clin Psychopharmacol. 1998 Mar;13 Suppl 3:S7-14
references.pmid: 9690964
references.citation: Rev Can Biol. 1961 Jun;20:425-49
references.pmid: 13903363
references.citation: J Clin Psychiatry. 1999 Feb;60(2):107-15
references.pmid: 10084637